Kaleido Biosciences, Inc. KLDO
OTC PK
| 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | |
|---|---|---|---|---|---|
| Revenue | 1.10M | 855.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.10M | 855.00K | -- | -- | -- |
| Cost of Revenue | 67.80M | 66.57M | -- | -- | -- |
| Gross Profit | -66.70M | -65.71M | -- | -- | -- |
| SG&A Expenses | 20.97M | 21.56M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -145.00K | 193.00K | -- | -- | -- |
| Total Operating Expenses | 88.63M | 88.32M | -- | -- | -- |
| Operating Income | -87.52M | -87.46M | -- | -- | -- |
| Income Before Tax | -90.29M | -90.03M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.29 | -90.03 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.29M | -90.03M | -- | -- | -- |
| EBIT | -87.52M | -87.46M | -- | -- | -- |
| EBITDA | -85.16M | -85.14M | -- | -- | -- |
| EPS Basic | -2.16 | -2.24 | -- | -- | -- |
| Normalized Basic EPS | -1.35 | -1.40 | -- | -- | -- |
| EPS Diluted | -2.16 | -2.24 | -- | -- | -- |
| Normalized Diluted EPS | -1.35 | -1.40 | -- | -- | -- |
| Average Basic Shares Outstanding | 167.41M | 160.79M | -- | -- | -- |
| Average Diluted Shares Outstanding | 167.41M | 160.79M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |